IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection.
Oncoimmunology
; 9(1): 1790716, 2020 07 09.
Article
in En
| MEDLINE
| ID: mdl-32934886
ABSTRACT
IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8+ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Interleukin-15
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Oncoimmunology
Year:
2020
Document type:
Article
Affiliation country: